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While neutron therapy was a highly topical subject in the 70s and 80s, today there are 
only a few remaining facilities offering fast neutron therapy (FNT). Nevertheless, up to 
today more than 30,000 patients were treated with neutron therapy. For some indications 
like salivary gland tumors and malignant melanoma, there is clinical evidence that the 
addition of FNT leads to superior local control compared to photon treatment alone. FNT 
was available in Munich from 1985 until 2000 at the Reactor Neutron Therapy (RENT) 
facility. Patient treatment continued at the new research reactor FRM II in 2007 under 
improved treatment conditions, and today it can still be offered to selected patients as 
an individual treatment option. As there is a growing interest in high-linear energy transfer 
(LET) therapy with new hadron therapy centers emerging around the globe, the clinical 
data generated by neutron therapy might help to develop biologically driven treatment 
planning algorithms. Also FNT might experience its resurgence as a combinational part-
ner of modern immunotherapies.
Keywords: fast neutron therapy, fast neutrons, reactor neutrons, rBe, adenoidcystic carcinoma, high-leT 
radiation
inTrODUcTiOn
Radiation therapy is one of the three essential pillars of cancer treatment. Today photon treatment 
delivered by linear accelerators is the most commonly used treatment modality. There is, however, 
a strong physical and biological rationale for the use of particle therapy in radiation oncology. Due 
to the high relative biological effectiveness (RBE), neutron beam therapy might offer an advantage 
compared to photon beam therapy, especially in the treatment of malignancies known to be radi-
oresistant (1, 2). This is a result of the high linear energy transfer (LET), which is in the range of 
about 200 keV/μm for 2 MeV neutron beams, about 200-fold higher than with conventional photon 
beams (3). The RBE for a 2 MeV neutron beam is estimated to be somewhere between 2 and 7 (4). 
This means that 1 Gy delivered by fast neutron therapy (FNT) should be as effective in killing cancer 
cells as 2–7 Gy of photon treatment. The numbers stated here implicate large uncertainties with the 
RBE varying between different tumor entities and even within the entities depending on the tumor 
TaBle 1 | current status of operating neutron facilities worldwide [status as stated at the iaea Technical Meeting 2013 (F1-TM-44771)].
location source Mean energy 
(MeV)
50% depth 
(cm)
Beam 
direction
collimator 
type
First patient 
treated
Patients 
treated (n)
University of Washington Medical Center, Seattle, USA Cyclotron 
p(50.5) + Be
20 14 Isocentric Multi leaf 1984 2960
iThemba Laboratory for Accelerator Based Science 
(LABS), Cape Town, South Africa
Cyclotron 
p(66) + Be
25 16 Isocentric Multi blade 
trimmer
1988 1788
Tomsk Polytechnic University, Tomsk, Russian Federation Cyclotron 
d(13.6) + Be
6.3 6 Horizontal Inserts 1983 1500
FRM II, Technische Universität München, Garching, 
Germany
Uranium 
converter
1.9 5 Horizontal Multi leaf 2007 124
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grading (5). Especially for brain tumors and late reacting tissues, 
the RBE is estimated to be in the upper part of the range (6).
Neutron therapy might be able to overcome the negative 
effect of tumor hypoxia, since the oxygen enhancement ratio 
of neutrons is only about 1.3 compared to up to 3 in photons 
(7). Furthermore, there is only a weak dependency on the cell 
cycle, meaning that non-proliferating cells can also be effectively 
targeted with neutron therapy (8).
International clinical trials were enthusiastically embraced 
from the mid 1970s through the mid 1980s, only to be abandoned 
in the late 1980s as clinicians observed unacceptable side effects. 
Although the number of patients treated with FNT up to today 
might be as high as 30,000, so far, large randomized studies 
comparing neutron therapy to standard photon radiation are not 
available and they will probably not be carried out in the future. 
For certain indications studies in the past clearly indicated a 
favorable outcome in terms of local control (LC) for neutron 
treatment compared to conventional photon treatment alone. 
This was shown for salivary gland tumors (9, 10), adenoidcystic 
carcinoma (ACC) of the trachea (11), prostate cancer (12, 13), 
pleural mesothelioma (14), or malignant melanomas (15, 16). 
Although most of these studies only recruited small patient 
numbers, for certain indications such as incompletely excised 
or unresectable salivary gland tumors, neutron therapy not only 
achieved superior LC (17) but also improved overall survival 
(OS) (18). To further increase the efficacy of neutron therapy and 
to reduce unwanted side effects, efforts were made to improve 
treatment conformality by introducing 3-D treatment planning 
systems (19–21). The Karmanos Cancer Center FNT facility 
in Detroit, MI, USA even had a delivery system for intensity 
modulated radiotherapy (IMRT) commissioned, but it was shut 
down in 2011. Up to today, four FNT facilities continue to operate 
worldwide as depicted in Table 1 (22).
Besides FNT, where mean neutron energies range between one 
and a few tens of MeV, neutron therapy can also be delivered as 
boron neutron capture therapy (BNCT). For this second branch 
of neutron therapy, low energy neutrons [thermal (<0.5 eV) or 
epithermal neutrons (0.5–10 keV)] but high neutron fluxes are 
needed (as they can be delivered by research reactors) and boron 
compounds are injected in order to selectively damage tumor 
cells. However, because patient treatment with BNCT was never 
carried out at the research reactor in Munich, results observed 
with BNCT will not be covered here and the difficulties regarding 
the compound biological effect (23), and the physical dose calcu-
lation will not be further discussed in this article.
This article aims to describe the experience gained with FNT 
in Munich within almost 30 years of clinical use and to outline 
how this experience might be of clinical relevance in modern 
particle therapy.
MaTerials anD MeThODs
neutron Therapy in Munich Between 1985 
and 2000 (FrM i)
Neutron treatment in Munich started at the first research reactor 
in the so called Reactor Neutron Therapy (RENT)-facility. From 
1985 until the shutdown of the reactor in 2000, 715 patients were 
treated with FNT. Treatment indications and patient numbers 
are depicted in Figure 1. The main treatment indications were 
curative treatment of salivary gland tumors, curative and pal-
liative treatment of head-and-neck cancers and palliative treat-
ment of breast cancer recurrences. Over the years the indication 
spectrum changed; while earlier patients were treated in curative 
intent for salivary gland tumors or other lesions, recently, treat-
ment has shifted to palliative indications, predominantly skin 
metastases mainly from breast cancer or malignant melanoma. 
Most of the patients were treated in combination with conven-
tional photon or electron beams, where FNT was applied as a 
local boost. Most commonly, 3–5 fractions at a single dose of 
2 Gy (physical dose, RBE approximately 3) were applied to the 
center of the tumor (24).
Of these 715 patients, 48 patients with ACC of the salivary 
glands were evaluated for LC and OS as well as for treatment 
related toxicities. Patients were at a median age of 55 years, and 
most patients had received surgery prior to FNT. After conven-
tional photon irradiation with 2 Gy single dose up to a median 
total dose of 50 Gy (range 50–56 Gy) a median neutron dose of 
6 Gy (range 4.5–7.5 Gy) at a median single dose of 1.5 Gy (range 
1.5  Gy–2  Gy) was applied. Patient characteristics in detail are 
shown in Table 2.
Moreover, 46 breast cancer patients with local recurrences 
on the thoracic wall were evaluated for initial treatment tumor 
response within the macroscopic tumor and for LC. Median time 
to ipsilateral chest wall recurrence after initial cancer treatment 
was 22 months (range 4–65 months). If the time interval between 
conventional photon RT within primary treatment and chest wall 
TaBle 2 | characteristics of patients with adenoidcystic carcinomas of 
the salivary glands treated with FnT.
n
Age (years) 55 (17–80)
Prior therapy
 Surgery 45 (94%)
 Biopsy 3 (6%)
Resection-status after surgery
 R0 12 (25%)
 R1/2 33 (69%)
Pathological Tumor Stage after surgery
 pT1/2 24 (44%)
 pT3/4 18 (38%)
Lymphatic spread 10 (21%)
FigUre 2 | layout of the FnT facility at the new research reactor 
(FrM ii): 1 reactor core, 2 neutron converter, 3 neutron beam line, 4 
reactor pool wall, 5 Filter unit, 6 Multi leaf collimator, 7 Treatment 
table, 8 Beam stopper.
FigUre 1 | Patient numbers and treatment indications of FnT at FrM i (renT facility) between 1985 and 2000.
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recurrence was shorter than 12 months, patients were treated with 
FNT only at a total dose of 10 Gy and a single dose of 2 Gy (1–2 
times a week). If the time interval between initial treatment and 
cancer recurrence was more than 12 months, first re-irradiation 
with conventional, normo-fractionated photon radiotherapy was 
applied to the area of recurrence up to a total dose of 30 Gy (2 Gy 
daily). Afterwards macroscopic tumor lesions received a neutron 
boost with a single dose of 2 Gy up to a total dose of 6 Gy (1–2 
times a week).
new research reactor – improved 
Treatment conditions at FrM ii
Treatment at the new research reactor Forschungs-
Neutronenquelle Heinz Maier-Leibnitz (FRM II) started in 2007 
under improved conditions. The most noticeable change is the 
installation of a multi leaf collimator (MLC) with a maximum field 
size of 30 cm2 × 20 cm2. Like RENT, the beam is characterized by 
a neutron–photon mix and applied at a dose rate of 0.52 Gy/min 
neutron dose and 0.20 Gy/min photon dose in a depth of 2 cm 
(25). Fast neutrons are generated by a nuclear fission reactor and 
a uranium converter plate. The patients can be positioned in front 
of the horizontal beam line by a 3-D motorized couch (Figure 2).
Between 2007 and 2013, 124 patients were treated, until the 
reactor was shut down due to major revisions. FNT continues 
since July 2015. Again, for most patients FNT was used as a local 
boost following external photon therapy. Patients treated at FRM 
II were between 19 and 94 years old (median 64) and the main 
primaries were breast cancer (40%), malignant melanoma (18%), 
and head-and-neck cancers (squamous 10%, ACC 15%, Figure 3). 
Most of the treatment indications were superficial skin lesions 
(69%) followed by salivary gland tumors (15%) and lymph node 
metastases (10%, Figure 4). A median total dose of 6 Gy (max 
12 Gy, min 1.4 Gy) at a median single dose of 2 Gy was applied. 
FigUre 3 | Primary tumors of patients treated with FnT between 2007 
and 2013 at FrM ii.
FigUre 4 | Treatment indications for FnT at FrM ii between 2007 and 
2013.
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For head-and-neck cancer patients thermoplastic mask systems 
were used and Computer tomography (CT) imaging acquired 
in treatment position was used to define the target volume and 
optimal beam positioning. For superficial skin lesion, the target 
volumes were determined clinically and light fields were used to 
define the optimal treatment position and MLC shape.
Thirty seven patients with superficial skin lesions were evaluated 
for tumor response and the effect of FNT on their quality of life (QoL) 
was also evaluated. A median total dose of 6 Gy (range 2–12 Gy) was 
applied at a median single dose of 2 Gy. Mean treatment field size 
was 12.6 (±6.6 cm) × 10.2 cm (±4.2 cm), and FNT was applied with 
a mean treatment time of 162 s (±23.5 s) per session.
ethics statement
All patients were treated in accordance with the principles of 
the Declaration of Helsinki. The scientific use of retrospective 
data has been explicitly allowed by Bavarian federal law (BayKrG 
Art 27(4)). Additionally, all patients gave their written informed 
consent and agreed that their scientific data could be used.
resUlTs
Due to the manifold treatment indications that were treated 
with FNT between 1985 and 2013, we focused on subgroup of 
patients for data presentation in the present manuscript in order 
to deliver data comparable to with other treatment possibilities. 
Therefore groups of patients were pooled according to the entity 
treated and the technique used and analyzed separately with 
special focus on LC, OS, and toxicity. Because of the relatively 
low numbers of patients treated with FNT compared to con-
ventional photon therapy and due to the individual character 
of FNT treatments, a thorough patient follow up was enforced. 
Patients were regularly seen in a dedicated outpatient depart-
ment and if patients did not show up for their appointment, 
their general practitioners were contacted for follow up and 
toxicity information.
Primary Treatment for adenoidcystic 
carcinomas of the salivary gland at renT
Patient data was analyzed at a median follow up time of 8 years 
(range 2–17 years). In terms of LC, only 15% of the patients showed 
local tumor progression within the initial site during follow-up. 
This resulted in LC rates at 5, 10, and 15 years of 90, 85, and 85%. 
Eighty percent of the patients were still alive after 5 years. This 
dropped to 60% after 10 years due to the development of distant 
metastases, as they are common in this tumor entity. Five patients 
(10%) showed severe late side effects in terms of skin toxicity 
with ulceration of the skin and seven patients (15%) developed 
osteonecrosis within the mandible.
Palliative Treatment for Thoracic Wall 
recurrences at renT
Patient data were analyzed at a median follow up time of 23 months 
(range 4–65 months). More than 2/3 of the patients (68%) showed 
complete remission of macroscopic chest wall metastases within 
the radiation field during follow up. Another 29% of the patients 
at least showed partial remission leaving only one patient without 
tumor response after FNT. Median time to tumor progression 
(in- and outside of the treatment field) was 9 month and LC after 
3 years was 55%. After FNT (with or without photon treatment) 
patients showed acute side effects with radiodermatitis up to 
grade II (CTCAE V4.0). During follow-up, five patients (10%) 
showed a grade II fibrosis within the treatment field, no grade III 
or IV side effects were observed.
Palliative Treatment for Metastatic skin 
lesions at FrM ii
In terms of tumor response macroscopic skin lesions showed a 
good response after FNT with 25% achieving complete remis-
sion, 56% partial remission and 19% had stable disease within the 
treated region at first follow up 6 weeks after completion of FNT. 
Nearly all patients (97%) stated that their personal situation was 
improved by the FNT.
FigUre 5 | Manuscripts on FnT (PubMed search: Fast neutron 
therapy, results pooled by decades).
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DiscUssiOn
Although FNT has been around since the 1970s, the number of 
publications on this topic is limited and unlike in most fields of 
oncology, the number of publications per year has not increased, 
but even decreased over the last decades (see Figure 5). This is 
explained by the clinical difficulties that developed during the 
application of FNT: In spite of benefits based on the biological 
properties of neutrons, the rates of treatment-induced side effects 
limited the widespread use of neutron therapy, and thus almost 
removed neutron centers from clinical radiation oncology (9, 
26, 27). For certain indications, however, few centers are still in 
operation, including also approaches with BNCT (28–30).
Due to the distinct physical features of neutrons, radiation 
protection remains challenging and high precision modern 
radiotherapy, as it can be delivered by a modern linear accelerator 
with photons, requires tremendous efforts in terms of costs and 
infrastructure to realize. Horrible side effects, which were caused 
in the early days of FNT when the new technique was enthusiasti-
cally embraced and the knowledge on dosing and treatment plan-
ning was not yet existent, sank deep into the collective memory 
(31–35). Also the clinical use of a fixed neutron RBE was bound to 
cause problems, despite good radiobiological data which showed 
its variability. There are several papers describing the theoretical 
difficulties associated with neutron RBE’s and how difficult it would 
be to improve the therapeutic ratio by using biological effective 
dose comparisons and modeling the relation between RBE and 
dose per fraction (36, 37). Therefore it seems like the radiation 
community is about to draw the veil of oblivion over FNT.
Even if the knowledge on FNT is still limited and the studies 
that were carried out so far will not hold up to today’s standard 
of randomized, well controlled studies and even if there are some 
authors who question an advantage of High-LET radiation in 
terms of tumor control at all (38) it can be stated that there is 
conclusive evidence on the capability of FNT to offer improved LC 
compared to photon treatment (9, 29, 39, 40). And this is also true 
for tumor entities that are known to be resistant to conventional 
radiation treatment. However, even if LC can be achieved, this 
often does not lead to a favorable OS, since survival is often limited 
by early distant metastases, as it was just recently shown by Liao 
et al. (16) and as it is also supported by our data on ACC patients.
Therefore in most treatment indications, FNT is considered 
useful today, and OS might not be the appropriate tool to measure 
the treatment success. We saw some tremendous improvement in 
QoL for individual patients due to tumor regression and reduced 
effort in wound care. Most of the patients treated with FNT stated 
that they had profited from this treatment and that their personal 
situation was improved after FNT. The main reason for this is, as 
stated above, in our opinion the good tumor response. Since most 
lesions treated were superficial, the treatment success was also 
easily comprehensible to the patient. So it can be stated that for 
superficial metastases, FNT offers a well-tolerated and effective 
treatment option. The high RBE also leads to short treatment 
times and few treatment sessions, which adds to the attractiveness 
in terms of a palliative treatment option.
The experience made with FNT should be evaluated care-
fully since it might be useful not only to learn more about FNT 
itself, but also about high-LET particle therapy in general. Since 
neutron therapy has been around since the 1970s, there are 
long-term survivors that can help to identify risk and chances 
associated with heavy-particle therapy. It has to be mentioned in 
this regard that there is a potentially increased risk of secondary 
malignancies caused by neutron irradiation, especially to healthy 
tissues outside of the treatment field. Large concerted efforts such 
as the Euratom Allegro project are currently carried out to further 
evaluate this topic (41). In the treatment of patients with ACC of 
the salivary gland, we saw some patients with osteonecrosis of 
the mandibular bone. Of course the relative numbers of those 
complications are considerably high compared to the numbers 
we are accepting in the photon community. But it also has to be 
considered that some of these patients had large tumors that were 
already infiltrating the bone, so the reason for the osteonecrosis 
is not necessarily the treatment but the tumor itself. This fact is 
reflected by the high rate of incomplete resections (more than 
2/3 of the evaluated patients), and it can certainly be seen as a 
selection bias against FNT. But still, this is also a warning that 
high LET-radiation and comparatively high single doses might 
not be appropriate in sensitive areas, especially when the tools to 
determine the anatomical dose application are limited.
Another point, why it might be too early to forget about FNT, 
is the recent developments in cancer immunotherapy. In 2013, 
immunotherapy was elected as the breakthrough of the year 
(42). Now, even in some patients with metastasized melanoma, 
long-term survivors can be found (43). The combination of 
radiotherapy and immunotherapy seems to be a fruitful col-
laboration. Since immunotherapy is able to offer improved OS 
but often fails to achieve LC in progressive tumor lesions, local 
radiotherapy might prove to be an ideal combination. Not only 
can radiotherapy lead to LC within the treatment field, it can 
even cause tumor regression outside of the treatment field, the 
so called abscopal effects (44). So far neither the optimal time 
point to combine the modalities nor the optimal dosing schedule 
is known. But there is reason to believe if the radiotherapy would 
cause a greater immune-stimulatory effect, than the collaboration 
between the two treatment partners would be even more effective. 
FNT might be able to achieve this immune-stimulatory effect due 
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to its high LET. Since FNT is usually applied only once or twice 
per week, lymphocyte depletion within the treatment field, as it is 
caused by daily routine radiotherapy, might be less pronounced. 
Thus, especially in patients were immunotherapy is appropriate, 
such as malignant melanoma, combination with FNT for skin 
lesions could be a promising alternative.
cOnclUsiOn
Fast neutron therapy using reactor generated fission neutrons is 
limited due to the relatively low penetration depth of the beam. 
Therefore, in most cases, therapy is limited to superficial lesions 
as they often occur in recurrent breast cancer at the thoracic wall 
or in recurrent malignant melanoma (skin lesions). To measure 
the treatment success in these palliative concepts, determina-
tion of the OS or progression free survival might not be an 
appropriate tool. Some clinically meaningful improvements in 
terms of local tumor regression with relatively low side effects 
were observed, leading to improved QoL and a reduced effort for 
wound management for the individual patients. Patients treated 
with FNT should be treated within clinical study protocols and 
the remaining neutron facilities should share their experiences, 
as it is done for other hadron therapies as well (45). As there is 
a growing interest in high-LET therapy with a growing number 
of hadron therapy centers around the globe, the clinical data 
generated by neutron therapy might help to develop biologically 
driven treatment planning algorithms. Also recent advances in 
immunotherapy call to reevaluate the benefit of neutron therapy, 
where good local tumor control can be achieved within short 
treatment times and immune-modulatory effects might be more 
pronounced compared to conventional irradiation.
aUThOr cOnTriBUTiOns
Study design: HS, JW, WP, SC. Acquisition of data: HS, TN, 
WR. Analysis and interpretation of data: HS, SK, SC. Drafting 
of manuscript: HS. Initial critical revision: WR, FW, SK, JW, SC. 
Revision of manuscript: HS, JW, FW.
reFerences
1. Theron T, Slabbert J, Serafin A, Böhm L. The merits of cell kinetic parameters 
for the assessment of intrinsic cellular radiosensitivity to photon and high 
linear energy transfer neutron irradiation. Int J Radiat Oncol Biol Phys (1997) 
37(2):423–8. doi:10.1016/S0360-3016(96)00533-0 
2. Wambersie A, Hendry J, Gueulette J, Gahbauer R, Pötter R, Grégoire V. 
Radiobiological rationale and patient selection for high-LET radiation in 
cancer therapy. Radiother Oncol (2004) 73(Suppl 2):S1–14. doi:10.1016/
S0167-8140(04)80004-5 
3. Goodhead DT. Mechanisms for the biological effectiveness of high-LET 
radiations. J Radiat Res (1999) 40(Suppl):1–13. doi:10.1269/jrr.40.S1 
4. Schmid E, Schlegel D, Guldbakke S, Kapsch RP, Regulla D. RBE of nearly 
monoenergetic neutrons at energies of 36 keV-14.6 MeV for induction of 
dicentrics in human lymphocytes. Radiat Environ Biophys (2003) 42(2):87–94. 
doi:10.1007/s00411-003-0200-0 
5. Broerse JJ, Battermann JJ. Fast neutron radiotherapy: for equal or for better? 
Med Phys (1981) 8(6):751–60. doi:10.1118/1.594851 
6. Battermann JJ. Fast neutron therapy for advanced brain tumors. Int J Radiat 
Oncol Biol Phys (1980) 6(3):333–5. doi:10.1016/0360-3016(80)90142-X 
7. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mech-
anisms, and cellular response. Oncologist (2004) 9(Suppl 5):4–9. doi:10.1634/
theoncologist.9-90005-4 
8. Gragg RL, Humphrey RM, Thames HD Jr, Meyn RE. The response of Chinese 
hamster ovary cells to fast neutron radiotherapy beams. III. Variation in 
biological effectiveness with position in the cell cycle. Radiat Res (1978) 
76(2):283–91. doi:10.2307/3574779 
9. Laramore GE, Krall JM, Griffin TW, Duncan W, Richter MP, Saroja KR, et al. 
Neutron versus photon irradiation for unresectable salivary gland tumors: 
final report of an RTOG-MRC randomized clinical trial. radiation therapy 
oncology group. Medical research council. Int J Radiat Oncol Biol Phys (1993) 
27(2):235–40. doi:10.1016/0360-3016(93)90233-L 
10. Brackrock S, Krüll A, Röser K, Schwarz R, Riethdorf L, Alberti W. 
Neutron therapy, prognostic factors and dedifferentiation of adenoid 
cystic carcinomas (ACC) of salivary glands. Anticancer Res (2005) 
25(2B):1321–6. 
11. Bittner N, Koh WJ, Laramore GE, Patel S, Mulligan MS, Douglas JG. Treatment 
of locally advanced adenoid cystic carcinoma of the trachea with neutron 
radiotherapy. Int J Radiat Oncol Biol Phys (2008) 72(2):410–4. doi:10.1016/j.
ijrobp.2008.01.016 
12. Laramore GE, Krall JM, Thomas FJ, Russell KJ, Maor MH, Hendrickson FR, 
et  al. Fast neutron radiotherapy for locally advanced prostate cancer. Final 
report of radiation therapy oncology group randomized clinical trial. Am J 
Clin Oncol (1993) 16(2):164–7. doi:10.1097/00000421-199304000-00018 
13. Lindsley KL, Cho P, Stelzer KJ, Koh WJ, Austin-Seymour M, Russell KJ, et al. Fast 
neutrons in prostatic adenocarcinomas: worldwide clinical experience. Recent 
Results Cancer Res (1998) 150:125–36. doi:10.1007/978-3-642-78774-4_7 
14. Patel SA, Kusano AS, Truong A, Stelzer KJ, Laramore GE. Fast neutron radio-
therapy in the treatment of malignant pleural mesothelioma. Am J Clin Oncol 
(2015) 38(1):47–50. doi:10.1097/COC.0b013e3182880b7a 
15. Bremer M, Neuhofer C, Auberger T, Zimmermann FB, Kneschaurek P, Reuschel 
W, et al. Palliative radiotherapy of malignant melanoma with reactor fission neu-
tron therapy (RENT): a prospective study. Radiat Oncol Investig (1999) 7(2):118–
24. doi:10.1002/(SICI)1520-6823(1999)7:2<118::AID-ROI8>3.0.CO;2-6 
16. Liao JJ, Parvathaneni U, Laramore GE, Thompson JA, Bhatia S, Futran ND, 
et al. Fast neutron radiotherapy for primary mucosal melanomas of the head 
and neck. Head Neck (2014) 36(8):1162–7. doi:10.1002/hed.23428 
17. Krüll A, Schwarz R, Engenhart R, Huber P, Lessel A, Koppe H, et al. European 
results in neutron therapy of malignant salivary gland tumors. Bull Cancer 
Radiother (1996) 83:125s–9s. doi:10.1016/0924-4212(96)84897-3 
18. Stannard C, Vernimmen F, Carrara H, Jones D, Fredericks S, Hille J, et  al. 
Malignant salivary gland tumours: can fast neutron therapy results point 
the way to carbon ion therapy? Radiother Oncol (2013) 109(2):262–8. 
doi:10.1016/j.radonc.2013.08.013 
19. Garny S, Rühm W, Zankl M, Wagner FM, Paretzke HG. First steps towards 
a fast-neutron therapy planning program. Radiat Oncol (2011) 6:163. 
doi:10.1186/1748-717X-6-163 
20. Popescu A. Changes in prescribed doses for the Seattle neutron therapy sys-
tem. Phys Med Biol (2008) 53(11):2985–90. doi:10.1088/0031-9155/53/11/015 
21. Soderberg J, Alm Carlsson G, Ahnesjo A. Monte Carlo evaluation of a photon 
pencil kernel algorithm applied to fast neutron therapy treatment planning. 
Phys Med Biol (2003) 48(20):3327–44. doi:10.1088/0031-9155/48/20/005 
22. IAEA. Research reactor users’ network (RRUNs): advances in neutron therapy. 
IAEA Technical Meeting (F1-TM-44771). Mainz (2013).
23. Coderre JA, Morris GM, Micca PL, Hopewell JW, Verhagen I, Kleiboer 
BJ, et  al. Late effects of radiation on the central nervous system: role of 
vascular endothelial damage and glial stem cell survival. Radiat Res (2006) 
166(3):495–503. doi:10.1667/RR3597.1 
24. Clasen B, et  al. [Priniciples of fission neutron therapy for malignant 
head and neck cancer at the research reactor (RENT) of the Technische 
Universitaet Muenchen]. Otorhinolaryngol Nova (1991) 1:102–8. doi:10.105
5/s-2007-998223
25. Wagner FM, Kneschaurek P, Kastenmüller A, Loeper-Kabasakal B, Kampfer 
S, Breitkreutz H, et al. The Munich fission neutron therapy facility MEDAPP 
at the research reactor FRM II. Strahlenther Onkol (2008) 184(12):643–6. 
doi:10.1007/s00066-008-1878-3 
26. Spratt DE, Salgado LR, Riaz N, Doran MG, Tam M, Wolden S, et al. Results 
of photon radiotherapy for unresectable salivary gland tumors: is neutron 
November 2015 | Volume 5 | Article 2627
Specht et al. Experience with FNT in Munich
Frontiers in Oncology | www.frontiersin.org
radiotherapy’s local control superior? Radiol Oncol (2014) 48(1):56–61. 
doi:10.2478/raon-2013-0046 
27. Griffin TW. Fast neutron therapy: its promise and its past. Int J Radiat Oncol 
Biol Phys (1980) 6(3):387–8. doi:10.1016/0360-3016(80)90157-1 
28. Wang LW, Chen YW, Ho CY, Hsueh Liu YW, Chou FI, Liu YH, et  al. 
Fractionated BNCT for locally recurrent head and neck cancer: experience 
from a phase I/II clinical trial at Tsing Hua open-pool reactor. Appl Radiat Isot 
(2014) 88:23–7. doi:10.1016/j.apradiso.2013.11.134 
29. Kageji T, Nagahiro S, Mizobuchi Y, Matsuzaki K, Nakagawa Y, Kumada H. 
Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: 
comparison of clinical results obtained with BNCT and conventional treat-
ment. J Med Invest (2014) 61(3–4):254–63. doi:10.2152/jmi.61.254 
30. Zonta A, Pinelli T, Prati U, Roveda L, Ferrari C, Clerici AM, et  al. Extra-
corporeal liver BNCT for the treatment of diffuse metastases: what was learned 
and what is still to be learned. Appl Radiat Isot (2009) 67(7–8 Suppl):S67–75. 
doi:10.1016/j.apradiso.2009.03.087 
31. Errington RD, Ashby D, Gore SM, Abrams KR, Myint S, Bonnett DE, et al. 
High energy neutron treatment for pelvic cancers: study stopped because 
of increased mortality. BMJ (1991) 302(6784):1045–51. doi:10.1136/
bmj.302.6784.1045 
32. MacDougall RH, Orr JA, Kerr GR, Duncan W. Fast neutron treatment for 
squamous cell carcinoma of the head and neck: final report of Edinburgh ran-
domised trial. BMJ (1990) 301(6763):1241–2. doi:10.1136/bmj.301.6763.1241 
33. Schmitt G, Schnabel K, Sauerwein W, Scherer E. Neutron and neutron-boost 
irradiation of soft tissue sarcomas: a 4.5 year analysis of 139 patients. Radiother 
Oncol (1983) 1(1):23–9. doi:10.1016/S0167-8140(83)80004-8 
34. Steingraber M, Lessel A, Jahn U. Fast neutron therapy in treatment of soft 
tissue sarcoma  –  the Berlin-Buch study. Bull Cancer Radiother (1996) 83 
Suppl:122s–4s. doi:10.1016/0924-4212(96)84896-1 
35. Maor MH, Errington RD, Caplan RJ, Griffin TW, laramore GE, Parker RG, 
et  al. Fast-neutron therapy in advanced head and neck cancer: a collabo-
rative international randomized trial. Int J Radiat Oncol Biol Phys (1995) 
32(3):599–604. doi:10.1016/0360-3016(94)00595-C 
36. Dale RG, Jones B. The assessment of RBE effects using the concept of bio-
logically effective dose. Int J Radiat Oncol Biol Phys (1999) 43(3):639–45. 
doi:10.1016/S0360-3016(98)00364-2 
37. Jones B, Underwood TS, Carabe-Fernandez A, Timlin C, Dale RG. Fast neu-
tron relative biological effects and implications for charged particle therapy. Br 
J Radiol (2011) 84(Spec No 1):S11–8. doi:10.1259/bjr/67509851 
38. Suit H, DeLaney T, Goldberg S, Paganetti H, Clasie B, Gerweck L, et al. Proton 
vs carbon ion beams in the definitive radiation treatment of cancer patients. 
Radiother Oncol (2010) 95(1):3–22. doi:10.1016/j.radonc.2010.01.015 
39. Huber PE, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M, 
et  al. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, 
photons or mixed beam? Radiother Oncol (2001) 59(2):161–7. doi:10.1016/
S0167-8140(00)00273-5 
40. Wambersie A. Fast neutron therapy at the end of 1988 – a survey of the clinical 
data. Strahlenther Onkol (1990) 166(1):52–60. 
41. Ottolenghi A, Smyth V, Trott KR. The risks to healthy tissues from the use of 
existing and emerging techniques for radiation therapy. Radiat Prot Dosimetry 
(2011) 143(2–4):533–5. doi:10.1093/rpd/ncq524 
42. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. 
Science (2013) 342(6165):1432–3. doi:10.1126/science.342.6165.1432 
43. Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, et al. 
Long-term survival and immunological parameters in metastatic melanoma 
patients who responded to ipilimumab 10 mg/kg within an expanded access 
programme. Cancer Immunol Immunother (2013) 62(6):1021–8. doi:10.1007/
s00262-013-1418-6 
44. Barker CA, Postow MA. Combinations of radiation therapy and 
immunotherapy for melanoma: a review of clinical outcomes. 
Int J Radiat Oncol Biol Phys (2014) 88(5):986–97. doi:10.1016/j.
ijrobp.2013.08.035 
45. Combs SE, Djosanjh M, Pötter R, Orrechia R, Haberer T, Durante M, 
et al. Towards clinical evidence in particle therapy: ENLIGHT, PARTNER, 
ULICE and beyond. J Radiat Res (2013) 54(Suppl 1):i6–12. doi:10.1093/
jrr/rrt039 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Specht, Neff, Reuschel, Wagner, Kampfer, Wilkens, Petry and 
Combs. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
